Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [07/09/2025 07:33 PDT] BNTC Expected to Trade Down Short Term
• [07/02/2025 08:07 PDT] BNTC Expected to Trade Up After Bullish Patterns Develop
• [06/30/2025 07:09 PDT] BNTC Expected to Trade Down After Bearish Patterns Develop
• [05/16/2025 07:14 PDT] BNTC Expected to Trade Up After Bullish Patterns Develop